-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, CEyrS/gxKO5bBo6lh6eE6jqxPTM11K4xDMHh0vHFpkek6yLdFXBDfMqqDMtpcEwa XF1cpJ7OJnBertm4GNbnGw== 0001246360-08-002885.txt : 20081029 0001246360-08-002885.hdr.sgml : 20081029 20081029173358 ACCESSION NUMBER: 0001246360-08-002885 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20081027 FILED AS OF DATE: 20081029 DATE AS OF CHANGE: 20081029 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MEDTRONIC INC CENTRAL INDEX KEY: 0000064670 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 410793183 STATE OF INCORPORATION: MN FISCAL YEAR END: 0430 BUSINESS ADDRESS: STREET 1: 710 MEDTRONIC PKWY STREET 2: MS LC300 CITY: MINNEAPOLIS STATE: MN ZIP: 55432 BUSINESS PHONE: 7635144000 MAIL ADDRESS: STREET 1: 710 MEDTRONIC PKWY CITY: MINNEAPOLIS STATE: MN ZIP: 55432 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LaNeve Stephen CENTRAL INDEX KEY: 0001433817 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-07707 FILM NUMBER: 081148697 BUSINESS ADDRESS: BUSINESS PHONE: 763-514-4000 MAIL ADDRESS: STREET 1: 710 MEDTRONIC PKWY STREET 2: MS LC310 CITY: MINNEAPOLIS STATE: MN ZIP: 55432 4 1 form.xml PRIMARY DOCUMENT X0303 4 2008-10-27 false 0000064670 MEDTRONIC INC MDT 0001433817 LaNeve Stephen 710 MEDTRONIC PKWY MS LC310 MINNEAPOLIS MN 55432 false true false false SVP & Pres Spinal & Biologics Common Stock 183.933 I ESOP Common Stock 2008-10-27 4 A false 8279 0 A 36072.287 D Employee Stock Option (right to buy) 36.24 2008-10-27 4 A false 33113 0 A 2009-10-27 2018-10-27 Common Stock 33113 33113 D These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the grant date if the Company?s cumulative diluted earnings per share growth during the 36 month period ending on the last day of the Company?s fiscal year 2011 equals or exceeds a 5% compound annual growth rate, as determined by the Compensation Committee. James N. Spolar, Attorney-in-fact 2008-10-29 -----END PRIVACY-ENHANCED MESSAGE-----